Stocks in play: InnoCan Pharma Corp
Announces the launch of its licensing and commercialization strategy work with respect to cannabinoid (CBD) therapy in the veterinary field. The appointment of a dedicated internal team will foster engagement between Innocan and prospective clients in the veterinary field in order to explore potential collaborations and commercialization opportunities. Innocan's innovative CBD-based products have previously demonstrated promise in human clinical trials, InnoCan Pharma Corp shares C.INNO are trading unchanged at $0.25.
Read:
Interest in Gold Miners Increases as Bank Fiasco Causes Market to Seek Safe Haven Assets
Auto Giants Gobbling Up Critical Battery Metal Supply Chain Assets
Major Players Active in Cleaning Up the Voluntary Carbon Market Through Efficiency
Biotech Sector Delivering Increased Optimism in Battle Against Pancreatic Cancer